[ Alzheimer’s Drug Discovery Foundation – Funding for Innovative Clinical Trials for Frontotemporal Degeneration | Research Funding ]
Event details
| Date | 09.11.2020 |
| Category | Call for proposal |
Aim: Launched in 2016, the Treat FTD Fund is a joint effort by the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) to support clinical development of novel or repurposed drugs for FTD disorders. Running clinical trials in FTD patients will enable investigators to identify optimal approaches to targeting this unique patient population. The funding priorities for this RFP are:
Applications should include a confirmation of drug supply, an IRB-ready clinical trial protocol, and an explicit plan for data sharing and/or making available the results publicly available.
Funding: max. $2,000,000
Duration: 1-3 years, with potential for follow-up funding
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step, and are submitted through the ADFF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Deadlines: 09-November-2020 (letter of intent)
15-February-2021 (full proposal, by invitation)
Further information
- Patient Population: The targeted population should include both genetic and sporadic forms of any FTD disorder, including behavioral variant FTD, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, and FTD/ALS.
- Therapeutic Focus: While gene therapy approaches for the genetic causes of FTD disorders are of interest, we encourage applications that target some of the underlying mechanisms that may contribute to the sporadic forms of the disease. This RFP is agnostic to target and open to symptomatic and disease-modifying approaches. Both novel and repurposed therapies are encouraged.
- Clinical Design: The RFP will support clinical proof-of-concept and pilot proof-of-mechanism studies. Phase 0/1 studies in healthy volunteers assessing pharmacodynamic outcomes will also be accepted for review. Innovative clinical trial designs and exploratory endpoints are encouraged.
Applications should include a confirmation of drug supply, an IRB-ready clinical trial protocol, and an explicit plan for data sharing and/or making available the results publicly available.
Funding: max. $2,000,000
Duration: 1-3 years, with potential for follow-up funding
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step, and are submitted through the ADFF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Deadlines: 09-November-2020 (letter of intent)
15-February-2021 (full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free